Company intelligence / Profile preview

Tethys Technology

Emeryville, California, United Statestethystech.com ↗

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Tethys Bioscience developed and commercialized the PreDx Diabetes Risk Score—a multi-marker blood test predicting five-year type 2 diabetes risk. Over 15,000 tests were ordered by US physicians between launch (~2009) and mid–2010. The company also had products in development for first-time heart attack and osteoporotic fracture risks but there are no recent updates on further clinical results or commercialization beyond initial launch years.

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Diagnostic test (biomarker-based blood tests)Protein biomarker analysisMetabolite profiling technology
Industry: Protein Biomarker Diagnostics

Partnerships

Collaborated with academic researchers; specific pharma/biotech partnerships not detailed.

Beyond the preview

Go deeper on Tethys Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tethys Technology.

Explore the full profile